Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus

International Journal of Clinical Pharmacology and Therapeutics

Volumn 45, Issue 10, 2007, Pages 563-567

  Bogdanski, Pawel ^a   Pupek Musialik, D ^a   Dytfeld, J ^a   Jagodzinski, P P ^a   Jablecka, A ^a   Kujawa, A ^a   Musialik, K ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Atherosclerosis; Chemokine receptors; Diabetes; Inflammation; Insulin

Indexed keywords

C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CCR5; INSULIN; INTERLEUKIN 6; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INSULIN TREATMENT; MACROPHAGE; MALE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

EID: 34948900953     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP45563     Document Type: Article

References (18)

1. Arner P. Insulin resistance in Type 2 diabetes - role of the adipokines. Curr Mol Med. 2005; 5: 333-339.
2. Baldwin AS Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996; 14: 649-683.
3. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998; 394: 894-897.
4. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003; 108: 1527-1532.
5. Dandona P, Aljada A, Mohanty P. The antiinflammatory and potential antiatherogenic effect of insulin: a new paradigm. Diabetologia. 2002; 45: 924-930.
6. Dytfeld J, Bogdanski P, Pupek-Musialik D, Jagodzinski P, Kujawa A. Expression of chemokine receptor CCR5 in patients with Type 2 diabetes. Merkuriusz Lekarski. 2006; 20: 195-198.
7. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennet PH,, Knowler WC. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with Type 2 diabetes. Pima Diabetes Genes Group. Diabetes. 1998; 47: 821-830.
8. Kallmann BA, Huther M, Tubes M et al. Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease. Diabetes. 1997; 46: 237-243.
9. Keklikoglu N. The localization of Fos B, a member of transcription factor AP-1 family, in rat odontoblasts and pulpal undifferentiated ectomesenchymal cells. FHC. 2004; 42: 191-193.
10. Lisowska K, Bryl E, Soroczynska M, Witkowski JM. Modulation of CD40L antigen expression in Jurkat cells: involvement of protein kinase C activity. FHC. 2003; 41: 233-235.
11. Lohmann T, Laue S, Nietzschmann U. Reduced expression of Th1-associated chemokine receptors on peripheral blood lymphocytes at diagnosis of Type 1 diabetes. Diabetes. 2002; 51: 2474-2480.
12. Mueller A, Mahmoud NG, Goedecke MC, McKeating JA, Strange PG. Pharmacological characterization of the chemokine receptor, CCR5. Br J Pharmacol. 2002; 135: 1033-1043.
13. Nakajima K, Tanaka Y, Nomiyama T, Ogihara T, Piao L, Sakai K, Onuma T, Kawamori R. Chemokine receptor genotype is associated with diabetic nephropathy in Japanese with Type 2 diabetes. Diabetes. 2002; 51: 238-242.
14. Nakajima K, Tanaka Y, Nomiyama T, Ogihara T, Kanno R, Iwashita N, Sakai K, Watada H, Onuma T, Kawamori R. RANTES promoter genotype is associated with diabetic nephropathy in Type 2 diabetic subjects. Diabetes Care. 2003; 26: 892-898.
15. Onuffer JJ, Horuk R. Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharmacol Sci. 2002; 23: 459-467.
16. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology. 2005; 15: 16R-28R.
17. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999; 340: 115-126.
18. Tsimanis A, Kalinkovich A, Bentwich Z. Soluble chemokine CCR5 receptor is present in human plasma. Immunol Lett. 2005; 96: 55-61n.